Misra MC, Parshad R. Randomized clinical trial of micronized flavonoids in the early control of bleeding from acute internal haemorrhoids. Br J Surgery 2000;87:868-72. View abstract.

Cospite M. Double-blind, placebo-controlled evaluation of clinical activity and safety of Daflon 500 mg in the treatment of acute hemorrhoids. Angiology 1994;45:566-73. View abstract.

Di Carlo G, Mascolo N, Izzo AA, Capasso F. Flavonoids: Old and new aspects of a class of natural therapeutic drugs. Life Sci 1999;65:337-53. View abstract.

Villa P, Cova D, De Francesco L, et al. Protective effect of diosmetin on in vitro cell membrane damage and oxidative stress in cultured rat hepatocytes. Toxicology 1992;73:179-89. View abstract.

Craig WJ. Health-promoting properties of common herbs. Am J Clin Nutr 1999;70:491-9. View abstract.

Middleton E. Some biological properties of plant flavonoids. Ann Allergy 1988;61:53-7. View abstract.

Ho Y, Tan M, Seow-Choen F. Micronized purified flavonidic fraction compared favorably with rubber band ligation and fiber alone in the management of bleeding hemorrhoids. Dis Colon Rectum 2000;43:66-9. View abstract.

Pecking AP, Fevrier B, Wargon C, Pillion G. Efficacy of Daflon 500 mg in the treatment of lymphedema (secondary to conventional therapy of breast cancer). Angiology 1997;48:93-8.. View abstract.

Guilhou JJ, Dereure O, Marzin L, et al. Efficacy of Daflon 500 mg in venous leg ulcer healing: a double-blind, randomized, controlled versus placebo trial in 107 patients. Angiology 1997;48:77-85.. View abstract.

Cesarone, M. R., Belcaro, G., Rohdewald, P., Pellegrini, L., Ledda, A., Vinciguerra, G., Ricci, A., Gizzi, G., Ippolito, E., Fano, F., Dugall, M., Acerbi, G., Cacchio, M., Di Renzo, A., Hosoi, M., Stuard, S., and Corsi, M. Comparison of Pycnogenol and Daflon in treating chronic venous insufficiency: a prospective, controlled study. Clin Appl Thromb.Hemost. 2006;12(2):205-212. View abstract.

Korthuis, R. J. and Gute, D. C. Adhesion molecule expression in postischemic microvascular dysfunction: activity of a micronized purified flavonoid fraction. J Vasc.Res 1999;36 Suppl 1:15-23. View abstract.

Smith, P. D. Neutrophil activation and mediators of inflammation in chronic venous insufficiency. J Vasc.Res 1999;36 Suppl 1:24-36. View abstract.

Keenoy, B., Vertommen, J., and De, Leeuw, I. The effect of flavonoid treatment on the glycation and antioxidant status in Type 1 diabetic patients. Diabetes Nutr Metab 1999;12(4):256-263. View abstract.

Bergan, J. J., Schmid-Schonbein, G. W., and Takase, S. Therapeutic approach to chronic venous insufficiency and its complications: place of Daflon 500 mg. Angiology 2001;52 Suppl 1:S43-S47. View abstract.

Jantet, G. Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assEssment and quaLity of lIfe improvEment with micronized Flavonoids. Angiology 2002;53(3):245-256. View abstract.

Cesarone, M. R., Belcaro, G., Pellegrini, L., Ledda, A., Vinciguerra, G., Ricci, A., Di Renzo, A., Ruffini, I., Gizzi, G., Ippolito, E., Fano, F., Dugall, M., Acerbi, G., Cornelli, U., Hosoi, M., and Cacchio, M. Venoruton vs Daflon: evaluation of effects on quality of life in chronic venous insufficiency. Angiology 2006;57(2):131-138. View abstract.

Cospite, M. and Dominici, A. Double blind study of the pharmacodynamic and clinical activities of 5682 SE in venous insufficiency. Advantages of the new micronized form. Int Angiol. 1989;8(4 Suppl):61-65. View abstract.

Struckmann, J. R. and Nicolaides, A. N. Flavonoids. A review of the pharmacology and therapeutic efficacy of Daflon 500 mg in patients with chronic venous insufficiency and related disorders. Angiology 1994;45(6):419-428. View abstract.

Jean, T. and Bodinier, M. C. Mediators involved in inflammation: effects of Daflon 500 mg on their release. Angiology 1994;45(6 Pt 2):554-559. View abstract.

Godeberge, P. Daflon 500 mg in the treatment of hemorrhoidal disease: a demonstrated efficacy in comparison with placebo. Angiology 1994;45(6 Pt 2):574-578. View abstract.

Cypriani, B., Limasset, B., Carrie, M. L., le Doucen, C., Roussie, M., de Paulet, A. C., and Damon, M. Antioxidant activity of micronized diosmin on oxygen species from stimulated human neutrophils. Biochem Pharmacol 4-6-1993;45(7):1531-1535. View abstract.

Buckshee, K., Takkar, D., and Aggarwal, N. Micronized flavonoid therapy in internal hemorrhoids of pregnancy. Int J Gynaecol Obstet 1997;57(2):145-151. View abstract.

Guilhou, J. J., Fevrier, F., Debure, C., Dubeaux, D., Gillet-Terver, M. N., Guillot, B., Levesque, H., Marzin, L., Mignot, J., Ouvry, P., Pillion, G., Van, Landuyt H., Zuccarelli, F., and Nicolaides, A. N. Benefit of a 2-month treatment with a micronized, purified flavonoidic fraction on venous ulcer healing. A randomized, double-blind, controlled versus placebo trial. Int.J.Microcirc.Clin.Exp. 1997;17 Suppl 1:21-26. View abstract.

Rizk, S. M and Sabri, N. A. Evaluation of Clinical Activity and Safety of Dalfon® 500mg in Type 2 Diabetic Femal Patients. Saudi Pharmacetical Journal 3-17-2009;199-209.

Glinski, W, Chodynicka, B., Roszkiewicz, J., and et al. The beneficial augmentative effect of micronised purified flavonoid fraction (MPFF) on the healing of leg ulcers: an open, multicentre, controlled, randomised study. Phlebology. 1999;14(4):151-157.

Giannini I, Amato A, Basso L, Tricomi N, Marranci M, Pecorella G, Tafuri S, Pennisi D, Altomare DF. Flavonoids mixture (diosmin, troxerutin, hesperidin) in the treatment of acute hemorrhoidal disease: a prospective, randomized, triple-blind, controlled trial. Tech Coloproctol. 2015 Jun;19(6):339-45. View abstract.

Kumar RM, Van Gompel JJ, Bower R, Rabinstein AA. Spontaneous intraventricular hemorrhage associated with prolonged diosmin therapy. Neurocrit Care. 2011 Jun;14(3):438-40. View abstract.

Milano G, Leone S, Fucile C, Zuccoli ML, Stimamiglio A, Martelli A, Mattioli F. Uncommon serum creatine phosphokinase and lactic dehydrogenase increase during diosmin therapy: two case reports. J Med Case Rep. 2014 Jun 16;8:194. View abstract.

Rajnarayana K, Venkatesham A, Krishna DR. Bioavailability of diclofenac sodium after pretreatment with diosmin in healthy volunteers. Drug Metabol Drug Interact. 2007;22(2-3):165-74. View abstract.

Rajnarayana K, Venkatesham A, Nagulu M, Srinivas M, Krishna DR. Influence of diosmin pretreatment on the pharmacokinetics of chlorzoxazone in healthy male volunteers. Drug Metabol Drug Interact. 2008;23(3-4):311-21. View abstract.

Yoo HH, Lee M, Chung HJ, Lee SK, Kim DH. Effects of diosmin, a flavonoid glycoside in citrus fruits, on P-glycoprotein-mediated drug efflux in human intestinal Caco-2 cells. J Agric Food Chem. 2007 Sep 5;55(18):7620-5. View abstract.

Bedada SK, Neerati P. Modulation of CYP3A enzyme activity by diosmin and its consequence on carbamazepine pharmacokinetics in rats. Naunyn Schmiedebergs Arch Pharmacol. 2018;391(2):115-21. View abstract.

Burkina V, Zlabek V, Halsne R, Ropstad E, Zamaratskaia G. In vitro effects of the citrus flavonoids diosmin, naringenin and naringin on the hepatic drug-metabolizing CYP3A enzyme in human, pig, mouse and fish. Biochem Pharmacol. 2016;110-111:109-16 View abstract.

Bedada SK, Boga PK. Influence of diosmin on the metabolism and disposition of carbamazepine in healthy subjects. Xenobiotica. 2017;47(10):879-84. View abstract.

Bedada SK, Boga PK, Kotakonda HK. The effect of diosmin on the pharmacokinetics of fexofenadine in healthy human volunteers. Xenobiotica. 2017;47(3):230-35. View abstract.

Wang Y, Fang X, Ye L, Li Y, Shi H, Cao Y. A Randomized Controlled Trial Evaluating the Effects of Diosmin in the Treatment of Radicular Pain. Biomed Res Int. 2017;2017:6875968. View abstract.

Shoeb M, Ramana KV. Anti-inflammatory effects of benfotiamine are mediated through the regulation of the arachidonic acid pathway in macrophages. Free Radic Biol Med 2012;52(1):182-90. View abstract.

Russo R, Chandradhara D, De Tommasi N. Comparative bioavailability of two diosmin formulations after oral administration to healthy volunteers. Molecules. 2018;23(9). pii: E2174. View abstract.

Poór M, Boda G, Mohos V, et al. Pharmacokinetic interaction of diosmetin and silibinin with other drugs: Inhibition of CYP2C9-mediated biotransformation and displacement from serum albumin. Biomed Pharmacother. 2018;102:912-921. View abstract.

Danielsson G, Jungbeck C, Peterson K, Norgren L. A randomised controlled trial of micronized purified flavonoid fraction vs placebo in patients with chronic venous disease. Eur J Vasc Endovasc Surg. 2002;23(1):73-6. View abstract.

Rabe E, Agus GB, Roztocil K. Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial. Int Angiol. 2015;34(5):428-36. View abstract.

Agir MS, Eraslan G. The effect of diosmin against liver damage caused by cadmium in rats. J Food Biochem. 2019;43(9):e12966. View abstract.

Attia TM. Efficacy and Safety of Daflon in the Treatment of Idiopathic Epistaxis. Am J Rhinol Allergy. 2019;33(1):62-68. View abstract.

Bozdag M, Eraslan G. The effect of diosmin against lead exposure in rats. Naunyn Schmiedebergs Arch Pharmacol. 2019. View abstract.

Cacchio A, Prencipe R, Bertone M, et al. Effectiveness and safety of a product containing diosmin, coumarin, and arbutin (Linfadren) in addition to complex decongestive therapy on management of breast cancer-related lymphedema. Support Care Cancer. 2019;27(4):1471-1480. View abstract.

Feldo M, Wójciak-Kosior M, Sowa I, et al. Effect of Diosmin Administration in Patients with Chronic Venous Disorders on Selected Factors Affecting Angiogenesis. Molecules. 2019;24(18). pii: E3316. View abstract.

Sheikh P, Lohsiriwat V, Shelygin Y. Micronized purified flavonoid fraction in hemorrhoid disease: A systematic review and meta-analysis. Adv Ther. 2020;37(6):2792-2812. View abstract.

Bogachev VY, Boldin BV, Turkin PY. Administration of micronized purified flavonoid fraction during sclerotherapy of reticular veins and telangiectasias: Results of the national, multicenter, observational program VEIN ACT PROLONGED-C1. Adv Ther. 2018l;35(7):1001-1008. View abstract.

Sirlak M, Akar AR, Eryilmaz S, et al. Micronized purified flavonoid fraction in pretreating CABG patients. Tex Heart Inst J. 2010;37(2):172-7. View abstract.

Khryshchanovich VY, Nebylitsin YS, Kosinets VA. Efficacy of micronized purified flavonoid fraction-based venoactive therapy after endovenous mechanochemical obliteration: Prospective comparative study. Drugs Real World Outcomes. 2021. View abstract.

Gavrilov SG, Karalkin AV, Moskalenko YP, Grishenkova AS. Efficacy of two micronized purified flavonoid fraction dosing regimens in the pelvic venous pain relief. Int Angiol. 2021;40(3):180-186. View abstract.

Steinbruch M, Nunes C, Gama R, et al. Is nonmicronized diosmin 600?mg as effective as micronized diosmin 900?mg plus hesperidin 100?mg on chronic venous disease symptoms? Results of a noninferiority study. Int J Vasc Med. 2020;2020:4237204. View abstract.

Serra R, Ielapi N, Bitonti et al. Efficacy of a low-dose diosmin therapy on improving symptoms and quality of life in patients with chronic venous disease: Randomized, double-blind, placebo-controlled trial. Nutrients. 2021;13(3):999. View abstract.

Li T, Zhu W, Liu G, Fang C, Quan S. Diosmin for the prevention of ovarian hyperstimulation syndrome. Int J Gynaecol Obstet. 2020;149(2):166-170. View abstract.

Schastlivtsev I, Lobastov K, Barinov V, Kanzafarova I. Diosmin 600 in adjunction to rivaroxaban reduces the risk of post-thrombotic syndrome after femoropopliteal deep vein thrombosis: results of the RIDILOTT DVT study. Int Angiol. 2020;39(5):361-371. View abstract.

Sahin A, Kutluhan MA, Yildirim C, Urkmez A, Akan S, Verit A. Results of purified micronized flavonoid fraction in the treatment of categorized type III chronic pelvic pain syndrome: a randomized controlled trial. Aging Male. 2020;23(5):1103-1108. View abstract.

Akhmetzianov RV, Bredikhin RA. Clinical efficacy of conservative treatment with micronized purified flavonoid fraction in female patients with pelvic congestion syndrome. Pain Ther 2021;10(2):1567-1578. View abstract.

Bagnati M, Puricelli C, Bauce G, et al. Short-term effects of supplemental L-arginine, diosmin, troxerutin, and hesperidin in diabetic patients: A Pilot Study. Biomed Res Int 2021;2021:3508281. View abstract.

Bogachev V, Boldin B, Turkin P, Samenkov A, Dzhenina O. Micronized purified flavonoid fraction-based conservative treatment of chronic venous disease in a real-world setting. Future Cardiol 2022;18(10):777-785. View abstract.

Mansilha A, Caldevilla H, Puskás A, Lucien A, Roby L, Kirienko A. MPFF 1000 mg chewable once daily vs. MPFF 500 mg twice daily in chronic venous disease: the double-blind, randomized, non-inferiority CHEWY trial. Int Angiol 2022;41(6):464-475. View abstract.

Osama H, Hamed EO, Mahmoud MA, Abdelrahim MEA. The Effect of Hesperidin and Diosmin Individually or in Combination on Metabolic Profile and Neuropathy among Diabetic Patients with Metabolic Syndrome: A Randomized Controlled Trial. J Diet Suppl 2022. View abstract.